| 1 | Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial. (Phillips RM, Proudfoot JA, Davicioni E, Liu Y, Spratt DE, Simko JM, Den RB, Pollack A, Rosenthal SA, Sartor AO, Sweeney CJ, Attard G, Longoria L, Patel S, Straza MW, Efstathiou JA, Shah AB, Hoffman KE, Rodgers JP, Sandler HM, Feng FY, Tran PT) Eur Urol Oncol 2025 Aug;8(4):968-976 2 Citations |
| 1 | Factors influencing treatment of veterans with advanced prostate cancer. (Caram MEV, Burns J, Kumbier K, Sparks JB, Tsao PA, Chapman CH, Bauman J, Hollenbeck BK, Shahinian VB, Skolarus TA) Cancer 2021 Jul 01;127(13):2311-2318 10 Citations |
| 1 | Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM) Cancer 2017 Jul 01;123(13):2489-2496 17 Citations |
| 1 | Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. (Eng KH, Hanlon BM, Bradley WH, Szender JB) Gynecol Oncol 2015 Nov;139(2):228-35 29 Citations |
| 1 | Differential platelet levels affect response to taxane-based therapy in ovarian cancer. (Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK) Clin Cancer Res 2015 Feb 01;21(3):602-10 94 Citations |
| 1 | Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. (Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK) Mol Cancer Ther 2014 Jul;13(7):1750-7 29 Citations |
| 2 | Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. (Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J) J Thorac Oncol 2014 May;9(5):702-9 49 Citations |
| 1 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. (Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB) Gynecol Oncol 2012 Jul;126(1):47-53 69 Citations |
| 1 | Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. (Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, Sonoda Y, Abu-Rustum NR, Huh J, Barakat RR, Kattan MW, Chi DS) Gynecol Oncol 2012 Apr;125(1):25-30 58 Citations |
| 1 | How does TPF improve survival over PF? (Devisetty K, Wong SJ, Mell LK) Lancet Oncol 2011 May;12(5):419-20; author reply 421-2 3 Citations |
| 1 | Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer. (Chen Y, Pandya KJ, Hyrien O, Keng PC, Smudzin T, Anderson J, Qazi R, Smith B, Watson TJ, Feins RH, Johnstone DW) Int J Radiat Oncol Biol Phys 2011 Aug 01;80(5):1358-64 7 Citations |
| 2 | Carboplatin and docetaxel-induced acute pancreatitis: brief report. (Singh V, Devata S, Cheng YC) Int J Clin Oncol 2010 Dec;15(6):642-4 13 Citations |
| 1 | A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. (Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R) Invest New Drugs 2010 Oct;28(5):634-40 33 Citations |
| 1 | Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. (Symes JC, Siatskas C, Fowler DH, Medin JA) Cancer Gene Ther 2009 May;16(5):439-52 8 Citations |
| 1 | Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. (Symes JC, Kurin M, Fleshner NE, Medin JA) Mol Cancer Ther 2008 Sep;7(9):3018-28 22 Citations |
| 1 | Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 01;107(1):83-9 123 Citations |
| 1 | Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N) J Clin Oncol 2005 Apr 20;23(12):2694-702 510 Citations |
| 1 | Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. (Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH) Clin Cancer Res 2004 Nov 01;10(21):7220-8 72 Citations |
| 1 | Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. (Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd) Oncology 2004;66(4):303-9 34 Citations |
| 1 | Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. (Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA) Cancer 2003 Aug 01;98(3):610-7 11 Citations |
| 1 | Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. (Lenzi R, Yalcin S, Evans DB, Abbruzzese JL) Cancer Invest 2002;20(4):464-72 41 Citations |
